Dermira Inc (DERM) Insider Sells $81,210.00 in Stock

Dermira Inc (NASDAQ:DERM) insider Eugene A. Bauer sold 3,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $27.07, for a total transaction of $81,210.00. Following the transaction, the insider now directly owns 5,802 shares in the company, valued at $157,060.14. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Eugene A. Bauer also recently made the following trade(s):

  • On Monday, December 18th, Eugene A. Bauer sold 3,000 shares of Dermira stock. The stock was sold at an average price of $27.34, for a total transaction of $82,020.00.

Shares of Dermira Inc (NASDAQ DERM) traded down $0.63 during trading hours on Thursday, hitting $28.08. 992,008 shares of the stock traded hands, compared to its average volume of 759,267. The stock has a market capitalization of $1,136.04, a P/E ratio of -4.51 and a beta of 0.80. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira Inc has a 1-year low of $21.35 and a 1-year high of $38.75.

Several brokerages have issued reports on DERM. Leerink Swann reissued an “outperform” rating and set a $41.00 price objective (down from $47.00) on shares of Dermira in a research report on Tuesday, November 7th. Needham & Company LLC reissued a “buy” rating and set a $43.00 price objective (down from $46.00) on shares of Dermira in a research report on Tuesday, November 7th. Cantor Fitzgerald reissued a “buy” rating and set a $45.00 price objective on shares of Dermira in a research report on Monday, November 6th. BidaskClub raised shares of Dermira from a “hold” rating to a “buy” rating in a research report on Wednesday, December 20th. Finally, Guggenheim reissued a “buy” rating and set a $30.00 price objective on shares of Dermira in a research report on Thursday, December 14th. Three equities research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $41.00.

Several large investors have recently modified their holdings of the company. Wells Fargo & Company MN boosted its holdings in shares of Dermira by 4.0% in the third quarter. Wells Fargo & Company MN now owns 52,995 shares of the biopharmaceutical company’s stock valued at $1,431,000 after acquiring an additional 2,025 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Dermira by 66.8% during the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 2,203 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Dermira by 4.8% during the third quarter. New York State Common Retirement Fund now owns 49,993 shares of the biopharmaceutical company’s stock worth $1,350,000 after buying an additional 2,308 shares in the last quarter. Quantbot Technologies LP boosted its holdings in Dermira by 75.4% during the third quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 2,309 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in Dermira by 40.9% during the second quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock worth $281,000 after buying an additional 2,803 shares in the last quarter. 99.47% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/04/dermira-inc-derm-insider-sells-81210-00-in-stock.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply